The stock may react positively to the substantial improvement in operating performance and gross margins, but investors should monitor whether the company can maintain these margins and grow revenue further without the burden of non-recurring charges. The strategic pivot to focus on the First Defense franchise could drive future growth.
Price Chart
Executive Summary
ImmuCell Corporation reported unaudited financial results for 2025, showing a 4.3% increase in product sales to $27.6 million and a significant improvement in gross profit margin to 41.4% from 30% in 2024. Despite a net loss of $1.0 million, the company achieved $1.6 million in net operating income, a $3.3 million improvement year-over-year, driven by manufacturing efficiencies and higher volumes. The results were partially offset by non-recurring charges including a $2.7 million write-down of Re-Tain assets.
Key Financial Metrics
Key Facts
- 2025 product sales increased 4.3% year-over-year to $27.6 million
- Gross profit margin improved to 41.4% in 2025 from 30% in 2024
- Net loss was $1.0 million in 2025 versus $2.2 million in 2024
- Net operating income was $1.6 million in 2025 versus a $1.6 million operating loss in 2024
- Non-recurring charges in 2025 totaled $3.6 million, including $2.7 million Re-Tain asset write-down
- Cash and cash equivalents remained stable at $3.8 million
- Company announced strategic focus on its First Defense franchise
Financial Impact
Revenue increased by $1.15 million year-over-year while gross profit increased by $3.5 million due to improved margins. However, non-recurring charges of $3.6 million significantly impacted net results.
Risk Factors
- Significant non-recurring charges in 2025 mask underlying profitability concerns
- Continued decline in stockholders' equity from $27.5M to $27.1M
- Heavy reliance on First Defense franchise with discontinuation of Re-Tain strategy
- Operating cash flow remains modest at $2.5 million despite improved operating income
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-006912 |
| Document: iccc20260304_8k.htm | 0001437749-26-006912 |
| Document: 0001437749-26-006912-index-headers.html | 0001437749-26-006912 |
| Document: 0001437749-26-006912-index.html | 0001437749-26-006912 |
| Document: 0001437749-26-006912.txt | 0001437749-26-006912 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $10.79 $10.45 | ▼ −3.15% | ▼ −2.00% | $10.24 (−5.10%) |
May 8, 2026 24w ago | 8-K | $8.45 $9.91 | ▲ +17.28% | ▲ +17.36% | $10.24 (+21.18%) |
Apr 8, 2026 28w ago | 8-K | $7.19 $7.54 | ▲ +4.87% | ▲ +1.68% | $10.24 (+42.42%) |
Apr 8, 2026 28w ago | Press Release | $7.19 $7.54 | ▲ +4.87% | ▲ +1.68% | $10.24 (+42.42%) |
Mar 4, 2026 33w ago | 8-K | $6.35 $6.63 | ▲ +4.41% | ▲ +6.65% | $10.24 (+61.26%) |
Mar 4, 2026 33w ago | Press Release | $6.35 $6.63 | ▲ +4.41% | ▲ +6.65% | $10.24 (+61.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers